Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Systemic Anti Cancer Therapy (SACT) Cancer 52 Ralphael Oghagbon What is currently available and how do I gain access? Coverage Map Nationally Numbers in Treatment Top Regimens Area Team Data Completeness Benchmarking Post Chemo Mortality Hospital Data Completeness Top Regimens www.chemodataset.nhs.uk Coverage Map: A National Perspective So… what do the numbers tell us? February 14 to January ‘15 March 14 to February 15 Patients Receiving Drug Treatments Regimens Commenced 163,840 165,256 278,354 282,646 Cycles Commenced 774,958 790,868 The figures listed above represent the number of patients reported to the CIU through SACT, for whom treatment activity has been submitted for the period covering August 2013 through July 2014 inclusive. How good is the data nationally? SACT data completeness, March 2014 to February 2015 Key Increase in completeness since comparison period Decrease in completeness since comparison period No change in completeness since comparison period 100% completion (for non-mandatory items) M Mandatory item (always 100%) How do less common cancers compare to other diagnostic groups Can I find out how complete my hospital’s Rare Cancer data is? Top Regimens by Diagnostic Group Brain/CNS ICD10: C47, C69-C72 All submitting trusts aggregated Data received for October 2013 - September 2014. Patients aged 16 and over These reports are available at a provider level There are in excess of 109 regimens for this disease group Top Regimens by Diagnostic Group Sarcoma ICD10: C40-C41, C46, C49 or various morphology codes All submitting trusts aggregated Data received for October 2013 - September 2014. Patients aged 16 and over These reports are available at a provider level There are in excess of 165 regimens for this disease group Top regimens reported for gastro-intestinal stromal tumours Morphology: M8936 All submitting trusts aggregated Data received for October 2013 - September 2014. Patients aged 16 and over Top Regimens IMATINIB SUNITINIB REGORAFENIB TRIAL CHOP R DASATINIB <regimen(s) not recognised> CP-CCR3559 BI 836845 DOSE EXP WEEKLY SCH CP-CCR3941-ONX-0801 WEEKLY SCHEDULE SA-CCR3877-IMAT+BKM120-COMBINATION Total patients Total patients by Intent of Treatment Curative* Palliative Not recorded Total 32 (16%) 37 (18%) 133 (66%) 202 19 (56%) 15 (44%) 34 1 (3%) 13 (45%) 15 (52%) 29 1 (10%) 9 (90%) 10 1 (100%) 1 1 (100%) 1 7 (100%) 7 2 (100%) 2 1 (100%) 1 4 (100%) 4 33 (12%) 71 (25%) 180 (63%) 284 *Curative group includes adjuvant and neo-adjuvant intent Post Chemotherapy Mortality Analysis From 25th July 2014 all NHS providers of chemotherapy in England have been able to access their 30/60/90-day post chemotherapy mortality analysis through the secure online portal. This analysis is available by tumour group and will provide a national comparison. It is essential that clinical teams within provider organisations check the accuracy of their data and contact the team in Oxford where there are any possible discrepancies. A letter to Medical Directors and Lead Chemotherapy Consultants has been sent out raising awareness of these reports. Post Chemotherapy Mortality Analysis (2) For demonstration purposes only Post Chemotherapy Survival Analysis Less Common Cancer all treatment intents For demonstration purposes only Cancer Drugs Fund (CDF) data • NHS England is responsible for delivery of the Cancer Drugs Fund • Public Health England commissioned to audit Cancer Drugs Fund • Expectation for Cancer Drugs Fund treatments to be reported through SACT by each hospital Improving Stakeholder Engagement Members of the CIU team will be attending the following meetings: • NHS England Area Team Pharmacist Meeting • NHS England Chemotherapy Clinical Reference Group • Chemotherapy Clinical Information Group • NCIN Site Specific Clinical Reference Groups (SSCRG) e.g. CNS workshop, CTYA meeting Would you like to know more about SACT? Please contact the team, we are always happy to discuss the project or meet with you. E-mail: [email protected]